|
|
Article: Eisai Enters into In-licensing Agreement with Sepracor for Eszopiclone Insomnia Treatment.
- Article from:
- JCN Newswires
- Article date:
- July 27, 2007
CopyrightCOPYRIGHT 2007 Japan Corporate News Network K.K. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Tokyo, Japan, July 27, 2007 - (JCN Newswire) - Eisai Co., Ltd. and Sepracor Inc. signed an in-licensing agreement for the insomnia treatment eszopiclone (product name in the U.S.: LUNESTA(R)) on July 26, 2007 (the U.S. eastern time). In this agreement, Eisai will assume exclusive rights for development and marketing of this compound in Japan.
Eszopiclone is a non-benzodiazepine type allosteric GABA agonist discovered by Sepracor. With its short-acting feature that allows fewer interruptions during sleep, the compound may help patients with transient insomnia as well as chronic insomnia in the elderly. Furthermore, in clinical studies conducted in the U.S., the ...